Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET

Company Participants

Michael Wood - LifeSci Advisors

Chaim Lebovits - President and Chief Executive Officer

Stacy Lindborg - Co-Chief Executive Officer

Alla Patlis - Interim Chief Financial Officer

Kirk Taylor - Executive Vice President and Chief Medical Officer

Conference Call Participants

Jason McCarthy - Maxim Group

Operator

Greetings, and welcome to the Brainstorm Cell Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. As a reminder this call is being recorded.

And I'd now like to introduce your host for today's call, Mr. Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Michael Wood

Good morning and thank you for joining us this morning. Earlier today, Brainstorm issued a press release with its financial results for the second quarter of 2023, including a corporate update.

Before passing it over to the company for prepared remarks, I’d like to remind listeners that this conference call will contain numerous statements, descriptions, forecasts and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS, the sufficiency of the company's existing capital resources for continuing operations in 2023 and beyond, the safety and clinical effectiveness of neuron technology platform, clinical trials of neuron and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support its business planning efforts.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time-to-time in the company's SEC filings. The company's results may differ materially from those projected on today's call and the company undertakes no obligation to publicly update any forward-looking statements.

Joining us on the call this morning will be Chaim Lebovits, President and CEO of Brainstorm; Dr. Stacy Lindborg, Co-Chief Executive Officer; and Alla Patlis, Interim Chief Financial Officer. In addition Brainstorm’s Executive VP and Chief Medical Officer, Dr. Kirk Taylor is also on the call and will be available to answer your questions during the Q&A session.

So I'd like to turn the call now to Mr. Lebovits. Please go ahead.

Chaim Lebovits

Thank you, Michael. Thank you all who have joined us to discuss our Q2 2023 financial results and recent progress. Our main priorities right now are to prepare for the forthcoming advisory committee for NurOwn, our investigational therapy for the treatment of ALS and to make sure the company is prepared to make NurOwn available to patients. As announced in June, the FDA will convene a meeting of the Cellular Tissue and Gene Therapies Advisory Committee to review our BLA for NurOwn on September 27.